Discontinued — last reported Q4 '24
Amgen BeiGene — Total revenues remained flat by 0.0% to $64.75M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 107.2%, from $31.25M to $64.75M. Over 2 years (FY 2022 to FY 2024), BeiGene — Total revenues shows an upward trend with a 101.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates successful product adoption, market penetration, or favorable contract terms within the partnership, while a decrease may signal market saturation, competitive pressure, or changes in the collaboration agreement.
This metric represents the total gross revenue generated from the collaboration and commercialization agreement with Bei...
Similar to other strategic alliance revenue or co-promotion income reported by large-cap biopharmaceutical companies, this metric is often compared against total segment revenue or total corporate revenue to assess the contribution of external partnerships.
amgn_segment_beigene_total_revenues| FY'22 | FY'23 | FY'24 | |
|---|---|---|---|
| Value | $64.00M | $125.00M | $259.00M |
| YoY Change | — | +95.3% | +107.2% |